Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
14 May 2021Website:
http://veratx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 9 min agoDividend
Analysts recommendations
Institutional Ownership
VERA Latest News
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches.
BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to atacicept for the treatment of IgAN. The designation reflects the FDA's determination that, based on an assessment of data from the Phase 2b ORIGIN clinical trial of atacicept for IgAN, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN.
BRISBANE, Calif., May 25, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data presentations from its Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy (IgAN), showing that atacicept stabilized kidney function through 72 weeks and led to rapid improvements in hematuria. These data were presented at the 61st European Renal Association Congress (ERA24) being held in Stockholm.
The biotech added two new executives to its ranks. Both have considerable experience in healthcare industry management.
Vera Therapeutics is a clinical stage company that some analysts think could be worth $1 billion. The company could have an approved product for the treatment of IgA nephropathy by 2026.
The heavy selling pressure might have exhausted for Vera Therapeutics, Inc. (VERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Vera Therapeutics, Inc. (VERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Vera Therapeutics, Inc. (VERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept's potential as long-term disease-modifying IgAN therapy Atacicept showed continued protective titers to diphtheria and tetanus and balanced COVID infections vs. placebo in IgAN BRISBANE, Calif.
Vera Therapeutics, Inc. (VERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What type of business is Vera Therapeutics?
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
What sector is Vera Therapeutics in?
Vera Therapeutics is in the Healthcare sector
What industry is Vera Therapeutics in?
Vera Therapeutics is in the Biotechnology industry
What country is Vera Therapeutics from?
Vera Therapeutics is headquartered in United States
When did Vera Therapeutics go public?
Vera Therapeutics initial public offering (IPO) was on 14 May 2021
What is Vera Therapeutics website?
https://veratx.com
Is Vera Therapeutics in the S&P 500?
No, Vera Therapeutics is not included in the S&P 500 index
Is Vera Therapeutics in the NASDAQ 100?
No, Vera Therapeutics is not included in the NASDAQ 100 index
Is Vera Therapeutics in the Dow Jones?
No, Vera Therapeutics is not included in the Dow Jones index
When does Vera Therapeutics report earnings?
The next expected earnings date for Vera Therapeutics is 09 August 2024